Takeda Submits Safety Data For Alogliptin To U.S FDA
This article was originally published in PharmAsia News
Takeda Pharmaceuticals announced July 28 it submitted additional information to U.S. FDA in April regarding the DPP-4 inhibitor SYR-322 (alogliptin) and in combination with Actos (pioglitazone).
You may also be interested in...
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.